Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,128 public posts
Filter results
Bipolar Androgen Therapy vs Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
https://www.practiceupdate.com/C/114237/56?elsca1=emc_enews_topic-alert BAT-enza may be an effective therapy for patients with mCRPC with progression on abiraterone. Further research is required for optimal clinical use and to identify biomarkers to predict treatment efficacy.
https://www.practiceupdate.com/C/114237/56?elsca1=emc_enews_topic-alert BAT-enza may be an effective therapy for patients with mCRPC with progression on abiraterone. Further research is required for optimal clinical use and to identify biomarkers to predict treatment efficacy.
maley2711
in
Prostate Cancer Network
3 years ago
Enter trial of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer- Hurry
Malecare, along with our partners, is prescreening our community for a study of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Advanced Prostate Cancer
3 years ago
Lu 177 PSMA vs Cabazitaxel (Jevtana) in patients with mCRPC previously treated with Docetaxel and with a progressing PSA with values >/=20.
utm_source=newsletter_8712&utm_medium=email&utm_campaign=developments-on-the-horizon-targeted-molecular-therapies-in-the-treatment-of-metastatic-
castration
-resistant-prostate-cancer-mcrpc
utm_source=newsletter_8712&utm_medium=email&utm_campaign=developments-on-the-horizon-targeted-molecular-therapies-in-the-treatment-of-metastatic-
castration
-resistant-prostate-cancer-mcrpc
tango65
in
Advanced Prostate Cancer
3 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Radical prostatectomy & metastatic PCa.
Abiraterone plus prednisone in metastatic,
castration
-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-60. Knipper S, Dzyuba-Negrean C, Palumbo C et al. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
Abiraterone plus prednisone in metastatic,
castration
-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-60. Knipper S, Dzyuba-Negrean C, Palumbo C et al. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistan
"CONCLUSION This randomized trial establishes meaningful clinical activity and safety of BAT and supports additional study to determine its optimal clinical integration. BAT can sensitize CRPC to subsequent antiandrogen therapy. Further study is required to confirm whether sequential therapy with BAT
"CONCLUSION This randomized trial establishes meaningful clinical activity and safety of BAT and supports additional study to determine its optimal clinical integration. BAT can sensitize CRPC to subsequent antiandrogen therapy. Further study is required to confirm whether sequential therapy with BAT
snoraste
in
Advanced Prostate Cancer
3 years ago
The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited
OBJECTIVE To characterize the somatic mutational landscape across the disease spectrum of metastatic
castration
-sensitive prostate cancer (mCSPC) to elucidate a biological definition of oligometastatic CSPC.
OBJECTIVE To characterize the somatic mutational landscape across the disease spectrum of metastatic
castration
-sensitive prostate cancer (mCSPC) to elucidate a biological definition of oligometastatic CSPC.
podsart
in
Advanced Prostate Cancer
3 years ago
Sartor on BAT and genomic profiling (excerpts)
https://www.urotoday.com/video-lectures/asco-gu-2021-prostate-cancer/video/mediaitem/2018-baseline-pathogenic-mutations-in-metastatic-
castration
-resistant-prostate-cancer-patients-being-treated-with-high-dose-testosterone-oliver-sartor.html
https://www.urotoday.com/video-lectures/asco-gu-2021-prostate-cancer/video/mediaitem/2018-baseline-pathogenic-mutations-in-metastatic-
castration
-resistant-prostate-cancer-patients-being-treated-with-high-dose-testosterone-oliver-sartor.html
cigafred
in
Advanced Prostate Cancer
3 years ago
High Gleason low PSA - quit ADT?
Quoting from his post: "Systemic therapies - chemo, Zytiga, Xtandi, Erleada - increases time to
castration
resistance and prostate cancer survival in the newly diagnosed". My doc said the quoted study is flawed in its design and with lower levels of ADT than is now given.
Quoting from his post: "Systemic therapies - chemo, Zytiga, Xtandi, Erleada - increases time to
castration
resistance and prostate cancer survival in the newly diagnosed". My doc said the quoted study is flawed in its design and with lower levels of ADT than is now given.
Purple-Bike
in
Advanced Prostate Cancer
4 years ago
Metastasis Directed Therapy (MDT) is here to stay for Oligometastatic Patients !!! Part(1) SABR/SBRT
toxicity, 2)The primary endpoint of ADT-free survival was achieved by 34% of the MDT group and 8% of the surveillance group over 5 years, a significant difference that correlated to a hazard ratio (HR) of 0.57 in favor of active treatment. 3) Men who received MDT had a reduced likelihood of developing
castration
-resistant
toxicity, 2)The primary endpoint of ADT-free survival was achieved by 34% of the MDT group and 8% of the surveillance group over 5 years, a significant difference that correlated to a hazard ratio (HR) of 0.57 in favor of active treatment. 3) Men who received MDT had a reduced likelihood of developing
castration
-resistant
NPfisherman
in
Fight Prostate Cancer
3 years ago
Androgen Cycling Shows Promise in Castration-Resistant Prostate Cancer - MedPage Today - February 23, 2021
Looks like the Medical Community is finally catching up with the patient community; i.e.: [i]"I think the key result of this study is that sequencing testosterone and then anti-testosterone therapy, in this case enzalutamide, seems to be the ideal way [to modify the adaptive process]," Denmeade told
Looks like the Medical Community is finally catching up with the patient community; i.e.: [i]"I think the key result of this study is that sequencing testosterone and then anti-testosterone therapy, in this case enzalutamide, seems to be the ideal way [to modify the adaptive process]," Denmeade told
cujoe
in
Fight Prostate Cancer
3 years ago
Claim your spot in Immunotherapy Trial testing Opvido for prostate cancer. Hurry, please
Malecare, along with our partners, is prescreening our community for a study of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Advanced Prostate Cancer
3 years ago
What if your loved one could get access to free immunotherapy treatment using Nivolumab, also known as OPDIVO?
Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Prostate Cancer Caregivers
3 years ago
What if you could get access to free immunotherapy treatment using Nivolumab, also known as OPDIVO?
Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Prostate Cancer And Gay Men
3 years ago
New randomized clinical trial of Lu-177-PSMA-617 for men who are still hormone sensitive
They haven't announced the sites yet, but with a sample size of 1126, I expect it will be the same as the VISION trial. https://clinicaltrials.gov/ct2/show/NCT04720157 They had previously announced a new trial for men who are
castration
-resistant and have failed one second-line hormonal agent, but have
They haven't announced the sites yet, but with a sample size of 1126, I expect it will be the same as the VISION trial. https://clinicaltrials.gov/ct2/show/NCT04720157 They had previously announced a new trial for men who are
castration
-resistant and have failed one second-line hormonal agent, but have
Tall_Allen
in
Advanced Prostate Cancer
3 years ago
Exclusive Fasttrak - Apply to clinical trial testing a new immunotherapy for prostate cancer!
Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced
Castration
-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Advanced Prostate Cancer
3 years ago
Estrogen therapy rediscovered
In the following study, 79 % of the
castration
-resistant patients had a decline of more than 50% in their PSA value after switching to an estrogen therapy: https://www.annalsofoncology.org/article/S0923-7534(19)54901-8/pdf The median duration of the response was 3.5 months.
In the following study, 79 % of the
castration
-resistant patients had a decline of more than 50% in their PSA value after switching to an estrogen therapy: https://www.annalsofoncology.org/article/S0923-7534(19)54901-8/pdf The median duration of the response was 3.5 months.
GP24
in
Advanced Prostate Cancer
3 years ago
Eosinophils, Lymphocytes & ELR number crunching
A relevant paper, in essence saying that an increase in Eosinophils is a positive marker: A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic
Castration
-Resistant Prostate Cancer Who Receive Sipuleucel-TI https://cancerimmunolres.aacrjournals.org/content/canimm
A relevant paper, in essence saying that an increase in Eosinophils is a positive marker: A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic
Castration
-Resistant Prostate Cancer Who Receive Sipuleucel-TI https://cancerimmunolres.aacrjournals.org/content/canimm
Justfor_
in
Prostate Cancer Network
3 years ago
I vitro evidence for effectiveness of Simvastatin Metformin combination against Enzalutamide resistant CRPC
Malignant cells initially respond to ADT, but subsequently colonize and re-emerge as more aggressive phenotype known as
castration
resistant prostate cancer (CRPC).
Malignant cells initially respond to ADT, but subsequently colonize and re-emerge as more aggressive phenotype known as
castration
resistant prostate cancer (CRPC).
Graham49
in
Advanced Prostate Cancer
4 years ago
To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
In non-metastatic
castration
-resistant prostate cancer (PCa), all patients with a PSA doubling time of ≤6 months should receive one ARTA, whereas the others might wait until there is an acceleration in the kinetics of their PSA levels."
In non-metastatic
castration
-resistant prostate cancer (PCa), all patients with a PSA doubling time of ≤6 months should receive one ARTA, whereas the others might wait until there is an acceleration in the kinetics of their PSA levels."
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in PCa
) Consistent suppression of testosterone (T) to
castration
level remains critical in the management of
castration
-resistant prostate cancer (CRPC).
) Consistent suppression of testosterone (T) to
castration
level remains critical in the management of
castration
-resistant prostate cancer (CRPC).
pjoshea13
in
Advanced Prostate Cancer
4 years ago
1
...
24
25
26
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1005 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest